Effective impairment of myeloma cells and their progenitors by blockade of monocarboxylate transportation

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33568-33586

  Hanson, Derek James ^a   Nakamura, Shingen ^a   Amachi, Ryota ^a   Hiasa, Masahiro ^a   Oda, Asuka ^a   Tsuji, Daisuke ^a   Itoh, Kohji ^a   Harada, Takeshi ^a   Horikawa, Kazuki ^a   Teramachi, Jumpei ^a   Miki, Hirokazu ^b   Matsumoto, Toshio ^a   Abe, Masahiro ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TOKUSHIMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Lactate; Metabolism; Monocarboxylate transporter; Multiple myeloma

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALPHA CYANO 4 HYDROXY CINNAMATE; COUMARIC ACID; HEXOKINASE; HEXOKINASE II; LACTIC ACID; METFORMIN; MONOCARBOXYLATE TRANSPORTER 1; MONOCARBOXYLATE TRANSPORTER 2; MONOCARBOXYLATE TRANSPORTER 4; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; ALPHA-CYANO-4-HYDROXYCINNAMATE; AR C155858; COTRANSPORTER; MONOCARBOXYLATE TRANSPORT PROTEIN 1; MONOCARBOXYLATE TRANSPORTER; MUSCLE PROTEIN; SLC16A4 PROTEIN, HUMAN; SLC16A7 PROTEIN, HUMAN; THIOPHENE DERIVATIVE; URACIL;

ARTICLE; CELL MIGRATION; CELL PH; CELL SURVIVAL; COLONY FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG TARGETING; ENZYME INHIBITION; GLYCOLYSIS; HUMAN; HUMAN CELL; MULTIPLE MYELOMA CELL LINE; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CANCER STEM CELL; CELL DEATH; DRUG EFFECTS; GENE SILENCING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; PATHOLOGY; PH; TUMOR CELL LINE;

CELL DEATH; CELL LINE, TUMOR; COUMARIC ACIDS; GENE KNOCKDOWN TECHNIQUES; HUMANS; HYDROGEN-ION CONCENTRATION; METFORMIN; MOLECULAR TARGETED THERAPY; MONOCARBOXYLIC ACID TRANSPORTERS; MULTIPLE MYELOMA; MUSCLE PROTEINS; NEOPLASTIC STEM CELLS; SYMPORTERS; THIOPHENES; URACIL;

EID: 84946086135     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5598     Document Type: Article

References (46)

1. Kawano Y, Moschetta M, Manier S, Glavey S, Gorgun GT, Roccaro AM, Anderson KC and Ghobrial IM. Targeting the bone marrow microenvironment in multiple myeloma. Immunol Rev. 2015; 263:160-172.
2. Dimopoulos MA, Richardson PG, Moreau P and Anderson KC. Current treatment landscape for relapsed and/or refractory multiple myeloma. Nat Rev Clin Oncol. 2015; 12:42-54.
3. Abe M, Harada T and Matsumoto T. Concise review: Defining and targeting myeloma stem cell-like cells. Stem Cells. 2014; 32:1067-1073.
4. Abe M. Targeting the interplay between myeloma cells and the bone marrow microenvironment in myeloma. Int J Hematol. 2011; 94:334-343.
5. Abe M, Hiura K, Wilde J, Moriyama K, Hashimoto T, Ozaki S, Wakatsuki S, Kosaka M, Kido S, Inoue D and Matsumoto T. Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood. 2002; 100:2195-2202.
6. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, Kido S, Oshima T, Shibata H, Ozaki S, Inoue D and Matsumoto T. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood. 2004; 104:2484-2491.
7. Oshima T, Abe M, Asano J, Hara T, Kitazoe K, Sekimoto E, Tanaka Y, Shibata H, Hashimoto T, Ozaki S, Kido S, Inoue D and Matsumoto T. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood. 2005; 106:3160-3165.
8. Sun X, Cheng G, Hao M, Zheng J, Zhou X, Zhang J, Taichman RS, Pienta KJ and Wang J. CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev. 2010; 29:709-722.
9. Azab AK, Runnels JM, Pitsillides C, Moreau AS, Azab F, Leleu X, Jia X, Wright R, Ospina B, Carlson AL, Alt C, Burwick N, Roccaro AM, Ngo HT, Farag M, Melhem MR, et al. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009; 113:4341-4351.
10. Alsayed Y, Ngo H, Runnels J, Leleu X, Singha UK, Pitsillides CM, Spencer JA, Kimlinger T, Ghobrial JM, Jia X, Lu G, Timm M, Kumar A, Cote D, Veilleux I, Hedin KE, et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood. 2007; 109:2708-2717.
11. Kashima K, Watanabe M, Sato Y, Hata J, Ishii N and Aoki Y. Inhibition of metastasis of rhabdomyosarcoma by a novel neutralizing antibody to CXC chemokine receptor-4. Cancer Sci. 2014; 105:1343-1350.
12. Muller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E and Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001; 410:50-56.
13. Turner JG, Gump JL, Zhang C, Cook JM, Marchion D, Hazlehurst L, Munster P, Schell MJ, Dalton WS and Sullivan DM. ABCG2 expression, function, and promoter methylation in human multiple myeloma. Blood. 2006; 108:3881-3889.
14. Nakanishi T and Ross DD. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression. Chin J Cancer. 2012; 31:73-99.
15. Cairns RA, Harris IS and Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011; 11:85-95.
16. Warburg O, Wind F and Negelein E. The Metabolism of Tumors in the Body. J Gen Physiol. 1927; 8:519-530.
17. Koppenol WH, Bounds PL and Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11:325-337.
18. Kato Y, Ozawa S, Miyamoto C, Maehata Y, Suzuki A, Maeda T and Baba Y. Acidic extracellular microenvironment and cancer. Cancer Cell Int. 2013; 13:89.
19. Halestrap AP. The monocarboxylate transporter family-Structure and functional characterization. IUBMB Life. 2012; 64:1-9.
20. Mathupala SP, Parajuli P and Sloan AE. Silencing of monocarboxylate transporters via small interfering ribonucleic acid inhibits glycolysis and induces cell death in malignant glioma: an in vitro study. Neurosurgery. 2004; 55:1410-1419; discussion 1419.
21. Fang J, Quinones QJ, Holman TL, Morowitz MJ, Wang Q, Zhao H, Sivo F, Maris JM and Wahl ML. The H+-linked monocarboxylate transporter (MCT1/SLC16A1): a potential therapeutic target for high-risk neuroblastoma. Mol Pharmacol. 2006; 70:2108-2115.
22. Baba M, Inoue M, Itoh K and Nishizawa Y. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun. 2008; 374:111-116.
23. Le Floch R, Chiche J, Marchiq I, Naiken T, Ilc K, Murray CM, Critchlow SE, Roux D, Simon MP and Pouyssegur J. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci U S A. 2011; 108:16663-16668.
24. Choi SY, Collins CC, Gout PW and Wang Y. Cancergenerated lactic acid: a regulatory, immunosuppressive metabolite? J Pathol. 2013; 230:350-355.
25. Lardner A. The effects of extracellular pH on immune function. J Leukoc Biol. 2001; 69:522-530.
26. Mendler AN, Hu B, Prinz PU, Kreutz M, Gottfried E and Noessner E. Tumor lactic acidosis suppresses CTL function by inhibition of p38 and JNK/c-Jun activation. Int J Cancer. 2012; 131:633-640.
27. Walenta S, Wetterling M, Lehrke M, Schwickert G, Sundfor K, Rofstad EK and Mueller-Klieser W. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers. Cancer Res. 2000; 60:916-921.
28. Webb BA, Chimenti M, Jacobson MP and Barber DL. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011; 11:671-677.
29. Nakano A, Miki H, Nakamura S, Harada T, Oda A, Amou H, Fujii S, Kagawa K, Takeuchi K, Ozaki S, Matsumoto T and Abe M. Up-regulation of hexokinaseII in myeloma cells: targeting myeloma cells with 3-bromopyruvate. J Bioenerg Biomembr. 2012; 44:31-38.
30. Fujiwara S, Kawano Y, Yuki H, Okuno Y, Nosaka K, Mitsuya H and Hata H. PDK1 inhibition is a novel therapeutic target in multiple myeloma. Br J Cancer. 2013; 108:170-178.
31. Sanchez WY, McGee SL, Connor T, Mottram B, Wilkinson A, Whitehead JP, Vuckovic S and Catley L. Dichloroacetate inhibits aerobic glycolysis in multiple myeloma cells and increases sensitivity to bortezomib. Br J Cancer. 2013; 108:1624-1633.
32. Walters DK, Arendt BK and Jelinek DF. CD147 regulates the expression of MCT1 and lactate export in multiple myeloma cells. Cell Cycle. 2013; 12:3175-3183.
33. Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, Fujii S, Kagawa K, Takeuchi K, Sakai A, Ozaki S, Okano K, et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PLoS One. 2011; 6:e27222.
34. Lagadic-Gossmann D, Huc L and Lecureur V. Alterations of intracellular pH homeostasis in apoptosis: origins and roles. Cell Death Differ. 2004; 11:953-961.
35. Mathupala SP, Ko YH and Pedersen PL. Hexokinase-2 bound to mitochondria: cancer's stygian link to the "Warburg Effect" and a pivotal target for effective therapy. Semin Cancer Biol. 2009; 19:17-24.
36. Ro TB, Holien T, Fagerli UM, Hov H, Misund K, Waage A, Sundan A, Holt RU and Borset M. HGF and IGF-1 synergize with SDF-1alpha in promoting migration of myeloma cells by cooperative activation of p21-activated kinase. Exp Hematol. 2013; 41:646-655.
37. Zhu J, Wu YN, Zhang W, Zhang XM, Ding X, Li HQ, Geng M, Xie ZQ and Wu HM. Monocarboxylate transporter 4 facilitates cell proliferation and migration and is associated with poor prognosis in oral squamous cell carcinoma patients. PLoS One. 2014; 9:e87904.
38. Barry MA and Eastman A. Endonuclease activation during apoptosis: the role of cytosolic Ca2+ and pH. Biochem Biophys Res Commun. 1992; 186:782-789.
39. Barry MA and Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys. 1993; 300:440-450.
40. Williams AC, Collard TJ and Paraskeva C. An acidic environment leads to p53 dependent induction of apoptosis in human adenoma and carcinoma cell lines: implications for clonal selection during colorectal carcinogenesis. Oncogene. 1999; 18:3199-3204.
41. Matsuyama S, Llopis J, Deveraux QL, Tsien RY and Reed JC. Changes in intramitochondrial and cytosolic pH: early events that modulate caspase activation during apoptosis. Nat Cell Biol. 2000; 2:318-325.
42. Segal MS and Beem E. Effect of pH, ionic charge, and osmolality on cytochrome c-mediated caspase-3 activity. Am J Physiol Cell Physiol. 2001; 281:C1196-1204.
43. Costa Leite T, Da Silva D, Guimaraes Coelho R, Zancan P and Sola-Penna M. Lactate favours the dissociation of skeletal muscle 6-phosphofructo-1-kinase tetramers downregulating the enzyme and muscle glycolysis. Biochem J. 2007; 408:123-130.
44. Mathupala SP, Ko YH and Pedersen PL. Hexokinase II: cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene. 2006; 25:4777-4786.
45. Arendt BK, Walters DK, Wu X, Tschumper RC, Huddleston PM, Henderson KJ, Dispenzieri A and Jelinek DF. Increased expression of extracellular matrix metalloproteinase inducer (CD147) in multiple myeloma: role in regulation of myeloma cell proliferation. Leukemia. 2012; 26:2286-2296.
46. Harada T, Ozaki S, Oda A, Tsuji D, Ikegame A, Iwasa M, Udaka K, Fujii S, Nakamura S, Miki H, Kagawa K, Kuroda Y, Kawai S, Itoh K, Yamada-Okabe H, Matsumoto T, et al. Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors. PLoS One. 2013; 8:e83905.